PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Innovative phase 2 trial targets advanced liver cancer

The UCL study will evaluate the safety and effectiveness of MTL-CEBPA in combination with second-line standard of care sorafenib versus the use of sorafenib in isolation

The first patient has been dosed in a clinical trial evaluating the use of a new therapy for an advanced type of liver cancer. MTL-EBPA with sorafenib is being analysed with a view to treating advanced hepatocellular carcinoma (HCC).

HCC is the most common type of primary liver cancer in adults and is the third leading cause of cancer-related deaths worldwide. It is also the most common cause of death in people with end of stage liver disease.

The global phase 2 OUTREACH-2 clinical trial will evaluate the safety and effectiveness of MTL-CEBPA in combination with second-line standard of care sorafenib, against sorafenib alone. Up to 150 patients will participate in the trial.

“Advanced liver cancer remains a significant unmet medical need, in particular for those patients who are resistant to frontline systematic therapy,” Professor Tim Meyer, Professor of Experimental Cancer Medicine at University College London and chief investigator of the study, commented.

“This combination treatment demonstrated intriguing signals of activity in a phase 1b trial, including durable and complete tumour responses. We believe that MTL-CEBPA’s immunological activity in the tumour microenvironment enables greater effectiveness of sorafenib and we are excited to seek to validate those early findings in this phase 2 clinical trial,” he added.

As the first-ever RNA therapy to enter the clinic, MTL-EBPA is being studied as a combination therapy in cancer. It works by reducing or removing one of the main defence mechanisms tumours use to resist attack by the immune system. This ensures the tumour can be attacked by tumour-targeting drugs as well as the immune system.

An RNA therapy is designed to correct the mutation in the RNA of someone with a genetic disease. In doing this, the RNA can be used to create missing proteins a cell needs and take away the underlying causes of diseases.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026